Pharmaceuticals

HPGC

HPGC released FY2026 Q1 earnings on April 22 After-Market (BJT), actual revenue CNY 4.175 B, actual EPS CNY 0.06

HPGC released FY2025 annual earnings on April 22 After-Market (BJT), actual revenue CNY 15.96 B (forecast CNY 18.17 B), actual EPS CNY 0.14 (forecast CNY 0.26)

HPGC released FY2025 Q4 earnings on April 22 After-Market (BJT), actual revenue CNY 3.943 B, actual EPS CNY 0.012

HPGC to Release FY2026 Q1 Earnings Report on April 23 After-Market BJT

HPGC to Release FY2025 Earnings on April 23 After-Market (BJT), Forecast Revenue CNY 18.17 B, EPS CNY 0.26

HPGC released FY2025 Q3 earnings on October 24 After-Market (BJT), actual revenue CNY 3.897 B, actual EPS CNY 0.0288

HPGC released FY2025 9 Months Earnings on October 24 After-Market BJT, actual revenue CNY 12.02 B, actual EPS CNY 0.1273

HPGC to Release FY2025 Q3 Earnings on October 25 After-Market (BJT)

HPGC released FY2025 Semi-Annual Earnings on August 22 After-Market (BJT), actual revenue CNY 8.125 B, actual EPS CNY 0.1

HPGC released FY2025 Q2 earnings on August 22 After-Market (BJT), actual revenue CNY 3.95 B, actual EPS CNY 0.0184

HPGC to Release FY2025 Semi-Annual Earnings on August 23, 2025 (BJT)

Huayao General Factory's Norfloxacin Capsules Pass Consistency Evaluation

Harbin Pharmaceutical Biotechnology Acquires Clinical Approval for Daprodustat Tablets

Harbin Pharmaceutical Plans to Lease Idle Factory Space to Improve Asset Utilization

Harbin Pharmaceutical Group Sijing Pharmaceutical to Acquire 42.82% Equity in Sijing Qianhe

Harpres Pharmaceutical Responds to Discrepancy Between Stock Price and Performance

Haramei Pharmaceutical Reports 59.10% YoY Net Profit Growth in 2024

HPGC released FY2024 Annual Earnings on April 25 After-Market (BJT), with actual revenue of CNY 16.18 B and actual EPS of CNY 0.25

HPGC released FY2025 Q1 earnings on April 25 Pre-Market (BJT), actual revenue CNY 4.174 B, actual EPS CNY 0.08

HPGC released FY2024 Q4 earnings on April 25 After-Market BJT, actual revenue CNY 3.919 B, actual EPS CNY 0.0494

600572

603896

600664

On April 3rd, Tmall Health, in collaboration with dozens of well-known domestic health supplement companies such as By-Health, Caltrate, Centrum, HPGC, 21st Century, CONBA, GNC, YANGYUAN, Shouxiangu, SenShan, and Nuohui, jointly launched the "Health Supplement Assurance Alliance." The alliance aims to promote standardization, normalization, and transparency in the health supplement industry, advocating for consumers to recognize the "blue hat" label when purchasing health supplements and to choose products that better meet the nutritional and health needs of Chinese people

36Kr

CONBA

Shouxiangu

YANGYUAN

ChinaAMC SSE STAR Biology and Medicine ETF

Guotai CSI Bio-medicine ETF

ChinaAMC Hang Seng Biotechnology Technology ETF(QDII)

Hwabao WP CSI Pharmaceuticals ETF

Bosera Hang Seng SCHK Innovative Drug Select ETF

ChinaAMC SSE Health Care ETF Initiating Fund

Founder Fubon CSI Medicine and Medical Device Innovation ETF

Ping An CSI Medicine and Medical Device Innovation ETF

E Fund Hang Seng SCHK Innovative Drug ETF

Huaan Hang Seng Biotech ETF

China Merchants CSI Biotechnology Theme ETF

ICBCCS SSE STAR Biology and Medicine ETF

Tianhong CNI BIOMEDICINE ETF

ChinaAMC CSI Biotechnology Theme ETF

Hwabao WP Hang Seng SCHK Innovative Drug Select ETF

GF CSI HK Innovative Drugs Industry ETF(QDII)

Bosera Hang Seng Health Care ETF(QDII)

Minsheng Royal CSI Biotechnology Theme ETF

Tmall Health has joined dozens of brands to establish the "Health Supplement Assurance Alliance"

According to the Zhitong Finance APP, HPGC disclosed its third-quarter report for 2025. The company's revenue for the first three quarters reached 12.021 billion yuan, a year-on-year decrease of 1.92%; the net profit attributable to shareholders was 329 million yuan, a year-on-year decrease of 35.35%; the net profit excluding non-recurring gains and losses was 289 million yuan, a year-on-year decrease of 38.56%; and the basic earnings per share were 0.13 yuan

Zhitong

HPGC released its performance for the first three quarters, with a net profit attributable to the parent company of 329 million yuan, a year-on-year decrease of 35.35%

HPGC announced that its subsidiary Harbin Pharmaceutical Group Sanjing Ming Shui Pharmaceutical Co., Ltd. has received the "Drug Supplement Application Approval Notice" issued by the National Medical Products Administration, confirming that Lacidipine tablets have passed the consistency evaluation of quality and efficacy for generic drugs. Lacidipine is an efficient calcium ion antagonist primarily used for dilating peripheral small arteries and lowering blood pressure, suitable for the treatment of hypertension

HPGC: Lercanidipine tablets pass the consistency evaluation for generic drugs

According to the Zhitong Finance APP, HPGC released its semi-annual report for 2025. During the reporting period, the company achieved operating revenue of 8.125 billion yuan, a year-on-year decrease of 0.21%. The net profit attributable to shareholders of the listed company was 260 million yuan, a year-on-year decrease of 24.37%. The net profit attributable to shareholders of the listed company after deducting non-recurring gains and losses was 244 million yuan, a year-on-year decrease of 21.71%. The basic earnings per share were 0.1 yuan

HPGC released its performance for the first half of the year, with a net profit attributable to the parent company of 260 million yuan, a year-on-year decrease of 24.37%

HPGC announced that its norfloxacin capsules (0.1g) have passed the consistency evaluation of quality and efficacy for generic drugs by the National Medical Products Administration. This approval will provide greater support for the drug in areas such as medical insurance reimbursement and procurement by medical institutions, helping to expand market share and enhance competitiveness, while also accumulating experience for the company's future generic drug products

HPGC: Norfloxacin capsules (0.1g) passed the consistency evaluation of quality and efficacy for generic drugs

HPGC announced that its wholly-owned subsidiary, HPGC Biotechnology Co., Ltd., has signed a "Technology Transfer Agreement" with Shanghai Bozhi Research and Development Co., Ltd. to purchase the clinical approval for Dapoxetine tablets and to collaborate on subsequent development and market launch matters. The total amount of the contract is expected to be 44.8 million yuan, with funding sourced from HPGC Biotechnology's own funds. The transaction does not constitute a related party transaction or a major asset restructuring and does not require submission for shareholder meeting approval

HPGC: Wholly-owned subsidiary signs "Technology Transfer Contract"

HPGC's wholly-owned subsidiary, HPGC Sanjing Pharmaceutical Co., Ltd., intends to acquire a 42.82% stake in Sanjing Qianhe for 23.446 million yuan. After the acquisition, Sanjing Qianhe will become its wholly-owned subsidiary. This move will optimize resource allocation, improve industrial layout, enhance market competitiveness, and promote the company's high-quality development, aligning with the long-term development and interests of all shareholders

Yinhua CSI Chinese Medicine ETF

HPGC's subsidiary plans to acquire a 42.82% stake in Sanjing Qianhe for 23.446 million yuan

HPGC announced that it will revitalize idle factories located in the Daowai District of Harbin by leasing them out. The leased factories include Building 03, Building 04, Building 05, Building 07, and Building 23, with a total construction area of 88,850.34 square meters. This move aims to improve asset utilization efficiency, generate stable rental income, and have a positive impact on the company's future financial condition

HPGC branch company lists part of its idle assets for lease

HPGC(600664.SH)